5281 California Avenue, Suite 100
Irvine, CA 92617
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead drug candidate, vibegron, is an oral, once-daily small molecule beta-3 adrenoreceptor agonist that is being evaluated for overactive bladder (OAB) in adults. Urovant Sciences intends to develop novel treatments for additional urologic conditions.